End Stage Renal Disease Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Merck Sharp & Dohme, Gilead Sciences, Aronora, Amgen, Rockwell Medical Technologies

DelveInsight's "End Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the End Stage Renal Disease, historical and forecasted epidemiology as well as the End Stage Renal Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the End Stage Renal Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; End Stage Renal Disease Market Forecast
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the End Stage Renal Disease Market Report:
• The End Stage Renal Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In April 2022, Fresenius Medical Care disclosed that the FDA in the United States has given approval for the Versi PD Cycler System. This is an advanced portable automated peritoneal dialysis system now authorized for use in North America.
• In March 2022, The Health Minister inaugurated a Hemodialysis unit at New Souillac in the presence of the World Health Representative to commemorate World Kidney Day in Mauritius. This new facility incorporates 22 hemodialysis machines with a capacity to serve approximately 150 patients, intending to enhance the decentralization of treatment for individuals affected by kidney disease.
• The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry gathered information on Renal Replacement Therapy (RRT) for End-Stage Renal Disease (ESRD) by compiling data from national and regional renal registries in Europe and neighboring countries around the Mediterranean Sea.
• Gender variations have been observed within the nephrology domain, indicating that women exhibit a certain degree of protection against developing End-Stage Renal Disease (ESRD). The overall occurrence of ESRD remains relatively low during the reproductive years, with an onset occurring approximately a decade later in women compared to men.
• As of December 31, 2018, approximately 0.7 million individuals (785,883) were undergoing treatment for End-Stage Renal Disease (ESRD) in the United States, resulting in a point prevalence of 2,382 cases per million population. Among these, the prevalence of dialysis treatment was 1,685 per million, while the prevalence of a functioning kidney transplant was 696 per million, according to the Centers for Disease Control and Prevention (2022).
• TRIFERIC is the initial and sole FDA-approved therapy designed for the replenishment of iron to sustain hemoglobin levels in adult individuals with hemodialysis-dependent chronic kidney disease (HDD-CKD).
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen, Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• The End Stage Renal Disease epidemiology based on gender analyzed that it can be concluded that ESRD is more common in males than females.
• The End Stage Renal Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage End Stage Renal Disease pipeline products will significantly revolutionize the End Stage Renal Disease market dynamics.

End Stage Renal Disease Overview
End-Stage Renal Disease (ESRD) is the final stage of chronic kidney disease (CKD), a condition in which the kidneys gradually lose their ability to function effectively over time. In ESRD, the kidneys are severely damaged and no longer able to perform their crucial functions, such as filtering waste products and excess fluids from the blood. As a result, individuals with ESRD require ongoing medical intervention or renal replacement therapy to maintain life.

Get a Free sample for the End Stage Renal Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

End Stage Renal Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

End Stage Renal Disease Epidemiology Segmentation:
The End Stage Renal Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of End Stage Renal Disease
• Prevalent Cases of End Stage Renal Disease by severity
• Gender-specific Prevalence of End Stage Renal Disease
• Diagnosed Cases of Episodic and Chronic End Stage Renal Disease
Download the report to understand which factors are driving End Stage Renal Disease epidemiology trends @ End Stage Renal Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

End Stage Renal Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the End Stage Renal Disease market or expected to get launched during the study period. The analysis covers End Stage Renal Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the End Stage Renal Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

End Stage Renal Disease Therapies and Key Companies
• TRIFERIC: Rockwell Medical Technologies
• AB002: Aronora
• MK-2060: Merck Sharp & Dohme
• Zepatier: Merck Sharp & Dohme
• Epclusa: Gilead Sciences
• Aranesp®: Amgen
• Erythrocyte Stimulating Agent (ESA): Rockwell Medical Technologies
• paricalcitol capsules: Abbott
• Astagraf XL: Astellas Pharma
• Tacrolimus: Veloxis Pharmaceuticals

Discover more about therapies set to grab major End Stage Renal Disease market share @ End Stage Renal Disease Treatment Landscape
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the End Stage Renal Disease Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key End Stage Renal Disease Companies: Rockwell Medical Technologies, Aronora, Merck Sharp & Dohme, Gilead Sciences, Amgen, Abbott, Astellas Pharma, Veloxis Pharmaceuticals, and others
• Key End Stage Renal Disease Therapies: TRIFERIC, AB002, MK-2060, Zepatier, Epclusa, Aranesp®, Erythrocyte Stimulating Agent (ESA), paricalcitol capsules, Astagraf XL, Tacrolimus, and others
• End Stage Renal Disease Therapeutic Assessment: End Stage Renal Disease current marketed and End Stage Renal Disease emerging therapies
• End Stage Renal Disease Market Dynamics: End Stage Renal Disease market drivers and End Stage Renal Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• End Stage Renal Disease Unmet Needs, KOL's views, Analyst's views, End Stage Renal Disease Market Access and Reimbursement

To know more about End Stage Renal Disease companies working in the treatment market, visit @ End Stage Renal Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. End Stage Renal Disease Market Report Introduction
2. Executive Summary for End Stage Renal Disease
3. SWOT analysis of End Stage Renal Disease
4. End Stage Renal Disease Patient Share (%) Overview at a Glance
5. End Stage Renal Disease Market Overview at a Glance
6. End Stage Renal Disease Disease Background and Overview
7. End Stage Renal Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of End Stage Renal Disease
9. End Stage Renal Disease Current Treatment and Medical Practices
10. End Stage Renal Disease Unmet Needs
11. End Stage Renal Disease Emerging Therapies
12. End Stage Renal Disease Market Outlook
13. Country-Wise End Stage Renal Disease Market Analysis (2019-2032)
14. End Stage Renal Disease Market Access and Reimbursement of Therapies
15. End Stage Renal Disease Market Drivers
16. End Stage Renal Disease Market Barriers
17. End Stage Renal Disease Appendix
18. End Stage Renal Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

End Stage Renal Disease Pipeline https://www.delveinsight.com/report-store/end-stage-renal-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"End Stage Renal Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the End Stage Renal Disease market. A detailed picture of the End Stage Renal Disease pipeline landscape is provided, which includes the disease overview and End Stage Renal Disease treatment guidelines.

End Stage Renal Disease Epidemiology https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'End Stage Renal Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted End Stage Renal Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Skin Burns Market
https://www.delveinsight.com/report-store/skin-burns-market
DelveInsight's "Skin Burns Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Skin Burns, historical and forecasted epidemiology as well as the Skin Burns market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
DelveInsight's "Thymus Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Thymus Cancer, historical and forecasted epidemiology as well as the Thymus Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Substance Use Disorder Market
https://www.delveinsight.com/report-store/substance-use-disorder-market
DelveInsight's "Substance Use Disorder Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance Use Disorder, historical and forecasted epidemiology as well as the Substance Use Disorder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tongue Cancer Market
https://www.delveinsight.com/report-store/tongue-cancer-market
DelveInsight's "Tongue Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Tongue Cancer, historical and forecasted epidemiology as well as the Tongue Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Tumor Ablation Market
https://www.delveinsight.com/report-store/tumor-ablation-market
DelveInsight's 'Tumor Ablation Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Tumor Ablation and the historical and forecasted Tumor Ablation market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Type 2 Diabetes Market
https://www.delveinsight.com/report-store/type-2-diabetes-market
DelveInsight's "Type 2 Diabetes Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of Type 2 Diabetes, historical and forecasted epidemiology as well as the Type 2 Diabetes market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

Varicose Vein Market
https://www.delveinsight.com/report-store/varicose-veins-market
DelveInsight's "Varicose Veins Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Varicose Veins, historical and forecasted epidemiology as well as the Varicose Veins market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.